Quest Diagnostics

Quest Diagnostics
Public
Traded as NYSE: DGX
S&P 500 Component
Industry Health care
Founded New York City, United States (1967)
Founder Paul Brown
Headquarters Madison, New Jersey, United States
Area served
United States, Brazil, Mexico, United Kingdom, India
Key people
Steve Rusckowski (CEO)
Revenue IncreaseUS$7.5 Billion (2015)[1]
IncreaseUS$1.4 Billion (2015)[1]
IncreaseUS$0.7 Billion(2015)[1]
Total assets IncreaseUS$10.0 Billion(2015)[1]
Total equity IncreaseUS$4.7 Billion (2015)[1]
Number of employees
44,000 (2015)[2]
Website QuestDiagnostics.com

Quest Diagnostics Incorporated is a Fortune 500 company providing clinical laboratory services with headquarters in Madison, New Jersey. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name on December 31, 1996. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico[3] and a laboratory in India[4] and also has collaborative agreements internationally with various hospitals and clinics.[5] It is a member of the Fortune 500 and the S&P 500, with corporate headquarters located in Madison, New Jersey. The company has approximately 44,000 employees, generates more than $7 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders.[2]

History

Controversies

Quest Diagnostics set a record in April 2009 when it paid $302 million to the government to settle a Medicare fraud case alleging the company sold faulty medical testing kits. It was the largest qui tam (whistleblower) settlement paid by a medical lab for manufacturing and distributing a faulty product.[13] In May 2011, Quest paid $241 million to the state of California to settle a False Claims Act case that alleged the company had overcharged Medi-Cal, the state’s Medicaid program, and provided illegal kickbacks as incentives for healthcare providers to use Quest labs.[14]

References

  1. 1 2 3 4 5 "Financial Statements for Quest Diagnostics". Google.com. Retrieved October 26, 2016.
  2. 1 2 "Quest Diagnostics 10-K SEC Filing". Quest Diagnostics 10-K SEC Filing. December 31, 2015. Retrieved October 26, 2016.
  3. "International Facilities & Operations". Quest Diagnostics. Retrieved 2012-02-15.
  4. "Birla Sun Life Insurance Names Quest Diagnostics its Exclusive Provider of Health Assessment Services in India". Quest Diagnostics. 2007-03-31. Retrieved 2012-02-15.
  5. "Our Growing International Presence". Quest Diagnostics. Retrieved 2012-02-15.
  6. "Quest Diagnostics Acquires Assets Of Diagnostics Medical Laboratory Inc.". Quest Diagnostics. Retrieved 2012-02-15.
  7. "Ciphergen Biosystems and Quest Diagnostics Form Strategic Alliance to Develop and Commercialize Tests Using Ciphergen's Proteomics Technology.". July 22, 2005. Retrieved Jul 26, 2013.
  8. Quest Diagnostics Successfully Completes Acquisition of Celera Archived July 9, 2011, at the Wayback Machine. May 17, 2011. Celera Corporation. Retrieved 2012-02-16.
  9. Anjali Athavaley. "Quest Diagnostics names Rusckowski as CEO". MarketWatch. Retrieved 18 May 2015.
  10. "DGX to Buy UMass Medical Lab (revised)". Yahoo Finance. 23 October 2012. Retrieved 18 May 2015.
  11. "Quest Diagnostics Acquires Solstas for $570M". News: Industry Watch (paper). 34 (4). 15 February 2014. p. 10.
  12. "Quest Diagnostics Completes Acquisition of Summit Health - Apr 21, 2014". newsroom.questdiagnostics.com. Retrieved 2015-07-16.
  13. "Businessman exposed problems with Quest subsidiary's blood test kits; led to $302 million settlement." Phillips & Cohen LLP press release. April 15, 2009.
  14. "Attorney General Kamala D. Harris announces $241 million settlement with Quest Diagnostics." State of California Department of Justice. May 19, 2011.
This article is issued from Wikipedia - version of the 12/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.